Marksans Pharma receives USFDA approval for Pregabalin Capsules

24 Jul 2022 , 01:33 AM

Marksans Pharma has received final approval from US Food Drugs Administration for its Abbreviated New Drug Application ANDA for Pregabalin Capsules 25 mg 50 mg 75 mg 100 mg 150 mg 200 mg 225 mg and 300 mg The product is bioequivalent and therapeutically equivalent to the reference listed drug RLD Lyrica Capsules 25 mg 50 mg 75 mg 100 mg 150 mg 200 mg 225 mg and 300 mg of Upjohn US 2 LLC Pregabalin capsules RLD Lyrica had estimated annual sales of USD 263 million in the US IQVIA MAT March 2022